Immune Infiltrate and Tumor Microenvironment Transcriptional Programs Stratify Pediatric Osteosarcoma into Prognostic Groups at Diagnosis

Author:

Marchais Antonin123,Marques da Costa Maria Eugenia12ORCID,Job Bastien4ORCID,Abbas Rachid56,Drubay Damien56ORCID,Piperno-Neumann Sophie7ORCID,Fromigué Olivia8ORCID,Gomez-Brouchet Anne910,Redini Françoise11,Droit Robin12,Lervat Cyril12,Entz-Werle Natacha1314,Pacquement Hélène7,Devoldere Catherine15,Cupissol Didier16,Bodet Damien17,Gandemer Virginie18,Berger Marc19,Marec-Berard Perrine20,Jimenez Marta21ORCID,Vassal Gilles3,Geoerger Birgit123ORCID,Brugières Laurence3,Gaspar Nathalie123

Affiliation:

1. 1National Institute for Health and Medical Research (INSERM) U1015, Gustave Roussy, Villejuif, France.

2. 2Université Paris-Saclay, Orsay, France.

3. 3Department of Oncology for Children and Adolescents, Gustave Roussy, Villejuif, France.

4. 4National Institute for Health and Medical Research (INSERM) US23, Gustave Roussy, Villejuif, France.

5. 5Service de Biostatistique et d'Epidémiologie, Gustave Roussy, Université Paris-Saclay, Villejuif, France.

6. 6Oncostat U1018, Inserm, Université Paris-Saclay, Équipe Labellisée Ligue Contre le Cancer, Villejuif, France.

7. 7Department of Medical Oncology, Institut Curie, Paris, France.

8. 8National Institute for Health and Medical Research (INSERM) UMR981, Gustave Roussy, Villejuif, France.

9. 9Pathology Department, IUCT-Oncopole, CHU and University of Toulouse, Toulouse, France.

10. 10National Centre for Scientific Research (CNRS), UMR5089, Toulouse, France.

11. 11Université de Nantes, Phy-OS, UMR_S 1238 Sarcomes osseux et remodelage des tissus calcifiés, Faculté de Médecine, Nantes, France.

12. 12Pediatric Oncology Unit-Adolescents and Young Adults, Centre Oscar Lambret, Lille, France.

13. 13Pediatric Onco-Hematology Department, University Hospital of Strasbourg, Strasbourg, France.

14. 14UMR CNRS 7021, Laboratory Bioimaging and Pathologies, Tumoral Signaling and Therapeutic Targets team, Faculty of Pharmacy, Illkirch, France.

15. 15CHU Amiens-Picardie, Amiens, France.

16. 16Department of Medical Oncology, Centre Val d'Aurelle, Montpellier, France.

17. 17Pediatric Onco-immuno-Hematology Department, CHU Caen, Caen, France.

18. 18CHU de Rennes, Hôpital Sud, Rennes, France.

19. 19Department of Pediatric Hematology and Oncology Unit, University Hospital of Saint-Etienne, Saint-Etienne, France.

20. 20Unité de Traitement de la Douleur de l'Enfant, Centre Léon Bérard, Institut d'Hématologie et d'Oncologie Pédiatrie, Lyon, France.

21. 21R&D Unicancer, Paris, France.

Abstract

Abstract The outcomes of adolescents/young adults with osteosarcoma have not improved in decades. The chaotic karyotype of this rare tumor has precluded the identification of prognostic biomarkers and patient stratification. We reasoned that transcriptomic studies should overcome this genetic complexity. RNA sequencing (RNA-seq) of 79 osteosarcoma diagnostic biopsies identified stable independent components that recapitulate the tumor and microenvironment cell composition. Unsupervised classification of the independent components stratified this cohort into favorable (G1) and unfavorable (G2) prognostic tumors in terms of overall survival. Multivariate survival analysis ranked this stratification as the most influential variable. Functional characterization associated G1 tumors with innate immunity and G2 tumors with angiogenic, osteoclastic, and adipogenic activities as well as PPARγ pathway upregulation. A focused gene signature that predicted G1/G2 tumors from RNA-seq data was developed and validated within an independent cohort of 82 osteosarcomas. This signature was further validated with a custom NanoString panel in 96 additional osteosarcomas. This study thus proposes new biomarkers to detect high-risk patients and new therapeutic options for osteosarcoma. Significance: These findings indicate that the osteosarcoma microenvironment composition is a major feature to identify hard-to-treat patient tumors at diagnosis and define the biological pathways and potential actionable targets associated with these tumors.

Funder

L'étoile de Martin

La Ligue contre le Cancer

SFCE/Fédération Enfants et Santé

Imagine4Margo

Parrainage médecin-chercheur

Fondation ARC pour la Recherche sur le Cancer

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 17 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3